The Clinical Features and Survival Outcome of 107 Newly Diagnosed Advanced Stage Extranodal NK/T-Cell Lymphoma Cases: A Triple-Center Study
Jiwei Li,1– 3 Jin Li,4,5 Meizuo Zhong,6 Hui Zhou,4,5 Baohua Yu1– 3 1Department of Pathology, Fudan University Shanghai Cancer Center, Shanghai, 200032, People’s Republic of China; 2Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, 200032, Peo...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Dove Medical Press
2021-02-01
|
| Series: | Cancer Management and Research |
| Subjects: | |
| Online Access: | https://www.dovepress.com/the-clinical-features-and-survival-outcome-of-107-newly-diagnosed-adva-peer-reviewed-article-CMAR |
| _version_ | 1818955787091836928 |
|---|---|
| author | Li J Li J Zhong M Zhou H Yu B |
| author_facet | Li J Li J Zhong M Zhou H Yu B |
| author_sort | Li J |
| collection | DOAJ |
| description | Jiwei Li,1– 3 Jin Li,4,5 Meizuo Zhong,6 Hui Zhou,4,5 Baohua Yu1– 3 1Department of Pathology, Fudan University Shanghai Cancer Center, Shanghai, 200032, People’s Republic of China; 2Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, 200032, People’s Republic of China; 3Institute of Pathology, Fudan University, Shanghai, 200032, People’s Republic of China; 4Department of Lymphoma and Hematology, Hunan Cancer Hospital, Changsha, People’s Republic of China; 5Department of Lymphoma and Hematology, The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha, People’s Republic of China; 6Department of Oncology, Xiangya Hospital, Central South University, Changsha, Hunan, People’s Republic of ChinaCorrespondence: Baohua YuDepartment of Pathology, Fudan University Shanghai Cancer Center, Shanghai, People’s Republic of ChinaEmail yubh2014@163.comHui ZhouDepartment of Lymphoma and Hematology, Hunan Cancer Hospital, Changsha, People’s Republic of ChinaEmail zhouhui9403@126.comObjective: Advanced stage extranodal natural killer/T-cell lymphoma (ENKTL) is a distinct type of non-Hodgkin lymphoma and the prognosis of ENKTL is poor with current treatment. This study aimed to investigate the clinical features, treatment strategy and survival outcome in patients with advanced stage ENKTL.Patients and Methods: A total of 107 patients with newly diagnosed advanced stage ENKTL between January 2010 and December 2014 were reviewed from three cancer centers. Survival probability was calculated using Kaplan-Meier and the survival curves were compared by Log rank test. Cox regression analyses was performed to investigate the prognostic factors in ENKTL.Results: The median patient age in our cohort was 42.0 years, with a male to female ratio of around 2.3:1. Over half of the patients had B symptoms (n = 61), high IPI scores (≥ 2, n = 60) and high Prognostic Index of Natural Killer Lymphoma (PINK) scores (≥ 3, n = 69). Elevated LDH level was present in around half of the patients (44/91). Most patients (n = 88) in our cohort originated in upper aerodigestive tract and the remaining 19 cases presented with non-upper aerodigestive tract involvement at first diagnosis. Chemotherapy regimens used in our study mainly include CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone) (n = 26), L-asparaginase (L-asp) containing chemotherapy (GELOXD (gemcitabine, l-asparaginase, oxaliplatin and dexamethasone) and SMILE (L-asparaginase, methotrexate, ifosfamide, etoposide, and dexamethasone)) (n = 66). No significant difference between the baseline clinical characteristics was found between the L-asp and CHOP group. The CR rate after treatment was 39.3% (42/107) for the whole cohort. The 3-year progression-free survival (PFS) and 3-year overall survival (OS) rate was 41.0% and 41.5%, respectively. The 3-year PFS (49.2% vs 26.5%, P = 0.048) and 3-year OS (49.4% vs 26.0%, P = 0.030) was significantly higher in the L-asp group than the CHOP group. Patient CR status and PINK score were proved to be significant independent factors affecting OS and PFS by multivariate analysis. The grade 3/4 hematologic toxicity (P = 0.0003) and non-hematologic toxicity (P = 0.0002) occurred more frequently in the SMILE group than the GELOXD group.Conclusion: Our results demonstrated that L-asp containing chemotherapy could provide favorable survival outcomes in patients with advanced stage ENKTL.Keywords: extranodal natural killer NK/T-cell lymphoma, chemotherapy, toxicity |
| first_indexed | 2024-12-20T10:43:36Z |
| format | Article |
| id | doaj.art-f599d761f8d14009850ae88d0fe1a3bb |
| institution | Directory Open Access Journal |
| issn | 1179-1322 |
| language | English |
| last_indexed | 2024-12-20T10:43:36Z |
| publishDate | 2021-02-01 |
| publisher | Dove Medical Press |
| record_format | Article |
| series | Cancer Management and Research |
| spelling | doaj.art-f599d761f8d14009850ae88d0fe1a3bb2022-12-21T19:43:30ZengDove Medical PressCancer Management and Research1179-13222021-02-01Volume 131541154962165The Clinical Features and Survival Outcome of 107 Newly Diagnosed Advanced Stage Extranodal NK/T-Cell Lymphoma Cases: A Triple-Center StudyLi JLi JZhong MZhou HYu BJiwei Li,1– 3 Jin Li,4,5 Meizuo Zhong,6 Hui Zhou,4,5 Baohua Yu1– 3 1Department of Pathology, Fudan University Shanghai Cancer Center, Shanghai, 200032, People’s Republic of China; 2Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, 200032, People’s Republic of China; 3Institute of Pathology, Fudan University, Shanghai, 200032, People’s Republic of China; 4Department of Lymphoma and Hematology, Hunan Cancer Hospital, Changsha, People’s Republic of China; 5Department of Lymphoma and Hematology, The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha, People’s Republic of China; 6Department of Oncology, Xiangya Hospital, Central South University, Changsha, Hunan, People’s Republic of ChinaCorrespondence: Baohua YuDepartment of Pathology, Fudan University Shanghai Cancer Center, Shanghai, People’s Republic of ChinaEmail yubh2014@163.comHui ZhouDepartment of Lymphoma and Hematology, Hunan Cancer Hospital, Changsha, People’s Republic of ChinaEmail zhouhui9403@126.comObjective: Advanced stage extranodal natural killer/T-cell lymphoma (ENKTL) is a distinct type of non-Hodgkin lymphoma and the prognosis of ENKTL is poor with current treatment. This study aimed to investigate the clinical features, treatment strategy and survival outcome in patients with advanced stage ENKTL.Patients and Methods: A total of 107 patients with newly diagnosed advanced stage ENKTL between January 2010 and December 2014 were reviewed from three cancer centers. Survival probability was calculated using Kaplan-Meier and the survival curves were compared by Log rank test. Cox regression analyses was performed to investigate the prognostic factors in ENKTL.Results: The median patient age in our cohort was 42.0 years, with a male to female ratio of around 2.3:1. Over half of the patients had B symptoms (n = 61), high IPI scores (≥ 2, n = 60) and high Prognostic Index of Natural Killer Lymphoma (PINK) scores (≥ 3, n = 69). Elevated LDH level was present in around half of the patients (44/91). Most patients (n = 88) in our cohort originated in upper aerodigestive tract and the remaining 19 cases presented with non-upper aerodigestive tract involvement at first diagnosis. Chemotherapy regimens used in our study mainly include CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone) (n = 26), L-asparaginase (L-asp) containing chemotherapy (GELOXD (gemcitabine, l-asparaginase, oxaliplatin and dexamethasone) and SMILE (L-asparaginase, methotrexate, ifosfamide, etoposide, and dexamethasone)) (n = 66). No significant difference between the baseline clinical characteristics was found between the L-asp and CHOP group. The CR rate after treatment was 39.3% (42/107) for the whole cohort. The 3-year progression-free survival (PFS) and 3-year overall survival (OS) rate was 41.0% and 41.5%, respectively. The 3-year PFS (49.2% vs 26.5%, P = 0.048) and 3-year OS (49.4% vs 26.0%, P = 0.030) was significantly higher in the L-asp group than the CHOP group. Patient CR status and PINK score were proved to be significant independent factors affecting OS and PFS by multivariate analysis. The grade 3/4 hematologic toxicity (P = 0.0003) and non-hematologic toxicity (P = 0.0002) occurred more frequently in the SMILE group than the GELOXD group.Conclusion: Our results demonstrated that L-asp containing chemotherapy could provide favorable survival outcomes in patients with advanced stage ENKTL.Keywords: extranodal natural killer NK/T-cell lymphoma, chemotherapy, toxicityhttps://www.dovepress.com/the-clinical-features-and-survival-outcome-of-107-newly-diagnosed-adva-peer-reviewed-article-CMARextranodal natural killer nk/t- cell lymphomachemotherapytoxicity. |
| spellingShingle | Li J Li J Zhong M Zhou H Yu B The Clinical Features and Survival Outcome of 107 Newly Diagnosed Advanced Stage Extranodal NK/T-Cell Lymphoma Cases: A Triple-Center Study Cancer Management and Research extranodal natural killer nk/t- cell lymphoma chemotherapy toxicity. |
| title | The Clinical Features and Survival Outcome of 107 Newly Diagnosed Advanced Stage Extranodal NK/T-Cell Lymphoma Cases: A Triple-Center Study |
| title_full | The Clinical Features and Survival Outcome of 107 Newly Diagnosed Advanced Stage Extranodal NK/T-Cell Lymphoma Cases: A Triple-Center Study |
| title_fullStr | The Clinical Features and Survival Outcome of 107 Newly Diagnosed Advanced Stage Extranodal NK/T-Cell Lymphoma Cases: A Triple-Center Study |
| title_full_unstemmed | The Clinical Features and Survival Outcome of 107 Newly Diagnosed Advanced Stage Extranodal NK/T-Cell Lymphoma Cases: A Triple-Center Study |
| title_short | The Clinical Features and Survival Outcome of 107 Newly Diagnosed Advanced Stage Extranodal NK/T-Cell Lymphoma Cases: A Triple-Center Study |
| title_sort | clinical features and survival outcome of 107 newly diagnosed advanced stage extranodal nk t cell lymphoma cases a triple center study |
| topic | extranodal natural killer nk/t- cell lymphoma chemotherapy toxicity. |
| url | https://www.dovepress.com/the-clinical-features-and-survival-outcome-of-107-newly-diagnosed-adva-peer-reviewed-article-CMAR |
| work_keys_str_mv | AT lij theclinicalfeaturesandsurvivaloutcomeof107newlydiagnosedadvancedstageextranodalnktcelllymphomacasesatriplecenterstudy AT lij theclinicalfeaturesandsurvivaloutcomeof107newlydiagnosedadvancedstageextranodalnktcelllymphomacasesatriplecenterstudy AT zhongm theclinicalfeaturesandsurvivaloutcomeof107newlydiagnosedadvancedstageextranodalnktcelllymphomacasesatriplecenterstudy AT zhouh theclinicalfeaturesandsurvivaloutcomeof107newlydiagnosedadvancedstageextranodalnktcelllymphomacasesatriplecenterstudy AT yub theclinicalfeaturesandsurvivaloutcomeof107newlydiagnosedadvancedstageextranodalnktcelllymphomacasesatriplecenterstudy AT lij clinicalfeaturesandsurvivaloutcomeof107newlydiagnosedadvancedstageextranodalnktcelllymphomacasesatriplecenterstudy AT lij clinicalfeaturesandsurvivaloutcomeof107newlydiagnosedadvancedstageextranodalnktcelllymphomacasesatriplecenterstudy AT zhongm clinicalfeaturesandsurvivaloutcomeof107newlydiagnosedadvancedstageextranodalnktcelllymphomacasesatriplecenterstudy AT zhouh clinicalfeaturesandsurvivaloutcomeof107newlydiagnosedadvancedstageextranodalnktcelllymphomacasesatriplecenterstudy AT yub clinicalfeaturesandsurvivaloutcomeof107newlydiagnosedadvancedstageextranodalnktcelllymphomacasesatriplecenterstudy |